Welcome to Skin cancer and Mesothelioma Cancer

Mesothelioma Cancer, Melanoma Cancer, Mesothelioma, Mesothelioma Lawyer
==================================================================

Tuesday, May 27, 2008

Mesothelioma Cancer an How Lives Are Affected

In this disease, malignant cells develop in the mesothelium, a protective lining that covers super of the length's internal organs. Its surpassingly unconfused site is the pleura (outer lining of the lungs and chest cavity), but it may also occur in the peritoneum (the lining of the abdominal cavity) or the pericardium (a sac that surrounds the heart).

 Malignancies involving mesothelial cells in these size cavities are known as malignant mesothelioma, which may be localized or diffuse. Mesothelioma is the word used to describe a cancerous tumor that involves the mesothelial cells of an organ, often the lungs, heart, or abdominal organs.

 

Mesothelioma is a savvy of cancer that is almost always caused by previous exposure to asbestos Malignant mesothelioma has also been linked to curing radiation using thorium dioxide and zeolite, a silicate in the soil.

 

 

Diagnosing mesothelioma is often difficult, because the symptoms are similar to those of a number of other conditions. Diagnosis begins with a review of the patient's medical history. Other symptoms of peritoneal mesothelioma may include bowel obstruction, blood clotting abnormalities, anemia, and fever. Shortness of breath, cough, and suffering in the chest due to an accumulation of fluid in the pleural space are often symptoms of pleural mesothelioma.

 Symptoms of peritoneal mesothelioma include weight loss and cachexia, abdominal swelling and aches and due to ascites (a buildup of fluid in the abdominal cavity).

 

Mesothelioma is diagnosed by pathological examination from a biopsy. Symptoms of mesothelioma may not appear until 20 to 50 years after exposure to asbestos. This is the end of a savvy that usually begins with symptoms that send most people to the doctor: a fluid build-up around the lungs (pleural effusions), shortness of breath, suffering in the chest, or pain or swelling in the abdomen.

 

Tissue is removed, placed under the microscope, and a pathologist makes a definitive diagnosis, and issues a pathology report. Malignant mesothelioma has a peak incidence 35-45 years after asbestos exposure. Transcendently people with malignant mesothelioma have on worked on jobs where they breathed asbestos. 

 

Malignant mesothelioma is often just called simply Mesothelioma and is a system of lung cancer that is quite rare. Malignant mesothelioma is more direct in men, with a male-to-female ratio of 3:1. Malignant mesothelioma is a rare type of cancer in which malignant cells are found in the sac lining the chest or abdomen. Most malignant mesotheliomas put complex karyotypes, with extensive aneuploidy and rearrangement of much chromosomes. It can also occur in children; however, these cases are not thought to be associated with asbestos exposure.

 

 

Exposure to airborne asbestos particles increases one's risk of developing malignant mesothelioma.

 Unlike lung cancer, there is no association between mesothelioma and smoking

 

The need for of radiation therapy in pleural mesothelioma has been shown to curtail pain in the majority of patients that are treated. But unfortunately, the duration of symptom control is short-lived. The 2 surgical procedures used are pleurectomy with decortication and extrapleural pneumonectomy.

 Radiation has no effect on survival, but it has caused significant palliation in 50% of patients treated for chest aches and and chest wall metastasis.

 

Surgical resection has been relied upon because radiation and chemotherapy require been ineffective absolute treatments. Pleurectomy with decortication is a more limited procedure and requires less cardiorespiratory reserve. It involves dissection of the parietal pleura, incision of the parietal pleura, and decortication of the visceral pleura followed by reconstruction. It has a morbidity rate of 25% and a mortality rate of 2%. It is a difficult procedure because the tumor encases the true to form pleura; the local recurrence rate is high.

Sunday, May 25, 2008

Fwd: Randomized and Non-randomized Prospective Controlled Cohort Studies in Matched Pair Design for the Long-term Therapy of Corpus uteri Cancer Patients with a Mistletoe Preparation (Iscador).



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, May 24, 2008 at 11:22 PM
Subject: Randomized and Non-randomized Prospective Controlled Cohort Studies in Matched Pair Design for the Long-term Therapy of Corpus uteri Cancer Patients with a Mistletoe Preparation (Iscador).
To: mesothelioma77@gmail.com


[1]Eur J Med Res. 2008 Mar 31; 13(3): 107-20
Grossarth-Maticek R, Ziegler R

Background: Mistletoe preparations such as Iscador are in common use as complementary/anthropo?sophic medications for many cancer indications, particularly for solid cancers. Efficacy of this complementary therapy is still discussed controversially. - Objective: Does the long-term therapy with Iscador show any effect on survival or psychosomatic self-regulation of patients with corpus uteri cancer? - Patients and Methods: Prospective recruitment and long-term follow-up in the following 4 controlled cohort studies. (1) Two randomized matched-pairs studies: corpus uteri cancer patients without (30 pairs) and with distant metastases (26 pairs) that never used any kind of mistletoe therapy were matched for prognostic factors. By pairwise random allocation, one of the patients was suggested mistletoe therapy to be applied by the attending physician. (2) Two non-randomized matched-pairs studies: corpus uteri cancer patients without (103 pairs) and with distant metastases (95 pairs) that already received mistletoe (Iscador) therapy were matched by the same criteria to control patients without Iscador therapy. - Results: Concerning overall survival in the randomized studies, a significant effect in favour of Iscador therapy was present only in the first study, the second showed no evidence for an effect: estimate of the hazard ratio and 95% confidence interval: 0.36 (0.16, 0.82) and 1.00 (0.46, 2.16) respectively. In the non-randomized studies, the results that adjusted for relevant prognostic variables were: 0.41 (0.26, 0.63), and 0.61 (0.39, 0.93). The effect of therapy with Iscador within 12 months on psychosomatic self-regulation as a measure of autonomous coping with the disease shows a significant rise in the Iscador group against the control group in the randomized as well as in the non-randomized study on patients with corpus uteri cancer without metastases: estimate of the median difference and 95% confidence interval: 0.40 (0.15, 0.70) and 0.70 (0.25, 1.15) respectively. - Conclusion: The mistletoe preparation Iscador in these studies has the effect of prolonging overall survival of corpus uteri cancer patients. Psychosomatic self-regulation as a measure of autonomous coping with the disease, rises significantly more under Iscador therapy than under conventional therapy alone.



___
Source: http://www.hubmed.org/display.cgi?uids=18499556
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc